Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool for managing patients with recurrent prostate cancer, and one of the most frequently employed radiopharmaceuticals is [68Ga]Ga-PSMA-11. Herein, we summarize the ...

Gallium (68 Ga) gozetotide or Gallium (68 Ga) PSMA-11, sold under the brand name Illuccix among others, is a radiopharmaceutical made of 68 Ga conjugated to a inhibitor of the enzyme prostate-specific membrane antigen (PSMA) known as Glu-Urea-Lys(Ahx)-HBED-CC.

Jul 23, 2021 · This radiopharmaceutical combines the peptidomimetic Glu-NH-CO-NH-Lys (Ahx)-HBED-CC with the radionuclide 68 Ga, enabling specific imaging of tumor cells expressing PSMA. Such a targeting approach may also be used for therapy planning as well as potentially for the evaluation of treatment response.

Ga 68 PSMA-11 Injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: • with suspected...

On 1 December 2020, almost 10 years after its discovery, [68 Ga]Ga-PSMA-11 was approved by the Food and Drug Administration (FDA) [1] as the first 68 Ga-labeled radiopharmaceutical for PET imaging of PSMA-positive prostate cancer.

Today, the U.S. Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) – the first drug for positron emission tomography (PET) imaging of prostate-specific membrane...

1 day ago · Objectives. To evaluate the relationship between total lesion PSMA (PSMA TL), serum PSA, histopathological findings and biochemical recurrence (BCR) in patients with localised prostate cancer (PCa).. Patients and methods. This retrospective study assessed men undergoing 68 Ga-PSMA-11 PET/CT for newly diagnosed or …

Feb 6, 2025 · PET and CT imaging studies using 68 Ga-labeled PSMA ligands demonstrated the specific localization of 68 Ga in PC lesions and distant metastatic lesions. [68 Ga]Ga-PSMA-R2 (68 Ga-PSMA-R2) is a PSMA-targeted PET/CT radiotracer with potential diagnostic applications.

Apr 8, 2025 · The study utilized 68Ga-PSMA-11 PET imaging to assess outcomes in prostate cancer patients treated with 177Lu-PSMA-617, focusing on whole-body SUVmean as a key parameter. Higher whole-body SUVmean quartiles were associated with significant improvements in radiographic progression-free survival and overall survival, highlighting its prognostic ...

Jan 17, 2025 · In this prospective study, the clinical utility of [68 Ga]Glu-urea-Lys (Ahx)-HBED-CC (68 Ga-PSMA-11) PET/CT for staging and risk stratification of treatment-naïve PCa was validated. The diagnostic value for patients with metastatic castrate-resistant prostate cancer (mCRPC) was …